Smokescreen Translational (TL) Analysis Platform

Investigators are developing a predictive genomic test to personalize smoking cessation treatment.
Principal
Details

Tobacco-attributable disease remains the largest potentially modifiable cause of mortality. Strategies to reduce smoking prevalence include developing more effective smoking cessation treatments. Using clinical and genomic data, investigators will develop prediction models of nicotine metabolism, nicotine dependence, and smoking cessation.

The investigators have previously designed Smokescreen®GTA, a genome-wide array that deeply captures variation in over 1,000 addiction genes, including the most important loci for nicotine metabolism and nicotine dependence. Prior research has identified multiple metabolic and regulatory genes, that with relatively few markers, can predict an individual’s nicotine metabolic activity.

In this study, researchers are developing a compact laboratory assay for genotyping DNA samples with specific markers and software to analyze clinical and genomic data (Smokescreen®TL).

Smokescreen®TL will be validated in smokers in clinical care. Ultimately, Smokescreen®TL will be available for use by health care providers interested in helping treatment seeking smokers quit.

This is a subaward with BioRealm from the National Institute on Alcohol Abuse and Alcoholism.

PROJECT PERIOD

9/1/18 - 8/31/21

FUNDING AGENCY

National Institute of Alcohol Abuse and Alcoholism (NIAAA)

PUBLICATIONS

Bergen, Andrew W., McMahan, Christopher S., McGee, Stephen, Ervin, Carolyn M., Tindle, Hilary A., Le Marchand, Loïc, Murphy, Daniel O., Patel, Yesha, M., Park, Sungshim L., & Baurley, James W. (2021) Multiethnic Prediction of Nicotine Biomarkers and Association with Nicotine Dependence. Nicotine & Tobacco Research.

Abstract or Full Text

Bergen AW, Do EK, Chen L-S, David SP. Tobacco genomics: Complexity and translational challenges. Nicotine Tob Res. 2019 Apr 24;21(6):705-706.

Abstract or Full Text

Panagiotou OA, Schuit E, Munafò MR, Bennett DA, Bergen AW, David SP. Smoking cessation pharmacotherapy based on genetically-informed biomarkers: What is the evidence? Nicotine Tob Res. 2019 Aug;21(9):1289-1293.

Abstract or Full Text

Baurley JW, McMahan CS, Ervin CM, Pardamean B, Bergen AW. Biosignature discovery for substance use disorders using statistical learning. Trends Mol Med. 2018 Feb;24(2):221-235.

Abstract or Full Text

Baurley, J. W., Edlund, C. K., Pardamean, C.,, Conti, D. V., Krasnow, R., Javitz, H. S., ... Bergen, A. W. Genome-wide association of the laboratory-based nicotine metabolite ratio in three ancestries. Nicotine Tob Res 2016 Sep;18(9):1837-44.

Abstract or Full Text